CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Aclaris Therapeutics Inc - ACRS CFD

Market is not available at the moment

Market information is presented
as of 2023-09-21

  • Summary
Trading Conditions
Spread 0.07
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026151 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026151%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003929 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003929%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Aclaris Therapeutics Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 14.01
Open* 14.02
1-Year Change* -1.68%
Day's Range* 13.84 - 14.36
52 wk Range 5.77-18.96
Average Volume (10 days) 943.88K
Average Volume (3 months) 13.87M
Market Cap 535.92M
P/E Ratio -100.00K
Shares Outstanding 70.79M
Revenue 31.17M
EPS -1.55
Dividend (Yield %) N/A
Beta 0.66
Next Earnings Date Nov 6, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Date Close Change Change (%) Open High Low
Jun 29, 2022 14.32 0.74 5.45% 13.58 14.37 13.50
Jun 28, 2022 14.01 -0.96 -6.41% 14.97 15.26 13.98
Jun 27, 2022 15.06 0.68 4.73% 14.38 15.72 14.38
Jun 24, 2022 14.41 -1.42 -8.97% 15.83 16.16 14.17
Jun 23, 2022 15.81 0.28 1.80% 15.53 16.17 15.13
Jun 22, 2022 15.43 0.01 0.06% 15.42 16.16 15.41
Jun 21, 2022 15.93 0.35 2.25% 15.58 16.52 15.58
Jun 17, 2022 15.57 0.97 6.64% 14.60 15.84 14.60
Jun 16, 2022 14.76 0.77 5.50% 13.99 14.88 13.99
Jun 15, 2022 14.72 0.89 6.44% 13.83 14.80 13.80
Jun 14, 2022 13.95 1.16 9.07% 12.79 14.00 12.65
Jun 13, 2022 12.91 -0.88 -6.38% 13.79 13.99 12.41
Jun 10, 2022 14.39 -0.22 -1.51% 14.61 14.90 14.17
Jun 9, 2022 15.04 0.06 0.40% 14.98 15.48 14.98
Jun 8, 2022 15.42 0.41 2.73% 15.01 15.86 15.01
Jun 7, 2022 15.39 1.36 9.69% 14.03 15.45 14.03
Jun 6, 2022 14.71 -0.02 -0.14% 14.73 14.94 14.44
Jun 3, 2022 14.70 0.48 3.38% 14.22 14.90 14.08
Jun 2, 2022 14.41 1.06 7.94% 13.35 14.94 13.35
Jun 1, 2022 13.32 0.66 5.21% 12.66 13.43 12.59

Aclaris Therapeutics Inc Events

Time (UTC) Country Event
Monday, November 6, 2023

Time (UTC)

13:30

Country

US

Event

Q3 2023 Aclaris Therapeutics Inc Earnings Release
Q3 2023 Aclaris Therapeutics Inc Earnings Release

Forecast

-

Previous

-
Wednesday, February 21, 2024

Time (UTC)

13:30

Country

US

Event

Q4 2023 Aclaris Therapeutics Inc Earnings Release
Q4 2023 Aclaris Therapeutics Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 29.752 6.761 6.482 4.227 6.151
Revenue 29.752 6.761 6.482 4.227 6.151
Total Operating Expense 119.606 96.484 57.394 115.285 90.931
Selling/General/Admin. Expenses, Total 25.133 23.619 20.53 27.827 25.761
Research & Development 77.813 43.813 31.731 64.899 60.841
Operating Income -89.854 -89.723 -50.912 -111.058 -84.78
Other, Net 2.946 -1.142 -0.424 -2.484 2.676
Net Income Before Taxes -86.908 -90.865 -51.336 -113.542 -82.104
Net Income After Taxes -86.908 -90.865 -51.154 -113.542 -82.104
Net Income Before Extra. Items -86.908 -90.865 -51.154 -113.542 -82.104
Net Income -86.908 -90.865 -51.015 -161.354 -132.738
Total Adjustments to Net Income
Income Available to Common Excl. Extra. Items -86.908 -90.865 -51.154 -113.542 -82.104
Income Available to Common Incl. Extra. Items -86.908 -90.865 -51.015 -161.354 -132.738
Diluted Net Income -86.908 -90.865 -51.015 -161.354 -132.738
Diluted Weighted Average Shares 65.2139 56.7306 42.5393 41.3239 32.9098
Diluted EPS Excluding Extraordinary Items -1.33266 -1.60169 -1.20251 -2.74761 -2.49482
Dividends per Share - Common Stock Primary Issue
Diluted Normalized EPS -1.26059 -1.17267 -1.20251 -2.29983 -2.49482
Cost of Revenue, Total 11.96 4.713 5.133 4.055 4.329
Gross Profit 17.792 2.048 1.349 0.172 1.822
Total Extraordinary Items 0 0 0.139 -47.812 -50.634
Depreciation / Amortization 0 0
Unusual Expense (Income) 4.7 24.339 0 18.504 0
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 1.869 2.528 7.753 19.018 1.528
Revenue 1.869 2.528 7.753 19.018 1.528
Cost of Revenue, Total 1.592 1.869 1.514 8.223 1.068
Gross Profit 0.277 0.659 6.239 10.795 0.46
Total Operating Expense 33.684 32.446 36.832 39.892 22.522
Selling/General/Admin. Expenses, Total 8.317 8.79 7.146 5.813 6.075
Research & Development 25.275 22.587 21.072 23.656 18.779
Unusual Expense (Income) -1.5 -0.8 7.1 2.2 -3.4
Operating Income -31.815 -29.918 -29.079 -20.874 -20.994
Other, Net 2.246 1.758 1.444 0.922 0.462
Net Income Before Taxes -29.569 -28.16 -27.635 -19.952 -20.532
Net Income After Taxes -29.569 -28.16 -27.635 -19.952 -20.532
Net Income Before Extra. Items -29.569 -28.16 -27.635 -19.952 -20.532
Total Extraordinary Items 0
Net Income -29.569 -28.16 -27.635 -19.952 -20.532
Income Available to Common Excl. Extra. Items -29.569 -28.16 -27.635 -19.952 -20.532
Income Available to Common Incl. Extra. Items -29.569 -28.16 -27.635 -19.952 -20.532
Diluted Net Income -29.569 -28.16 -27.635 -19.952 -20.532
Diluted Weighted Average Shares 70.6335 66.8728 66.7018 66.6753 65.99
Diluted EPS Excluding Extraordinary Items -0.41863 -0.4211 -0.41431 -0.29924 -0.31114
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.43986 -0.43306 -0.30786 -0.26625 -0.36266
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 231.55 205.032 57.493 83.803 179.499
Cash and Short Term Investments 217.571 191.414 54.131 75.015 167.972
Cash & Equivalents 45.277 27.349 22.063 35.937 57.019
Short Term Investments 172.294 164.065 32.068 39.078 110.953
Prepaid Expenses 13.495 12.995 2.59 3.118 4.802
Total Assets 254.596 251.211 70.784 98.297 275.566
Property/Plant/Equipment, Total - Net 3.779 4.772 5.783 7.203 2.287
Property/Plant/Equipment, Total - Gross 10.374 9.968 9.517 9.749 3.609
Accumulated Depreciation, Total -6.595 -5.196 -3.734 -2.546 -1.322
Long Term Investments 12.242 34.242
Other Long Term Assets, Total 0.052 0.117 0.385 0.092 68.003
Total Current Liabilities 21.938 22.931 14.874 22.432 27.342
Accounts Payable 10.351 9.985 5.254 9.917 14.755
Accrued Expenses 5.979 5.082 4.574 4.015 6.071
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 5.608 7.864 5.046 8.389 6.374
Total Liabilities 56.975 53.87 33.134 28.385 60.442
Total Long Term Debt 0 0 10.653 0.021 29.914
Other Liabilities, Total 34.67 30.572 7.24 5.383 2.637
Total Equity 197.621 197.341 37.65 69.912 215.124
Redeemable Preferred Stock 0 0 0 0 0
Common Stock 0.001 0.001 0.00045 0.00042 0
Additional Paid-In Capital 880.832 792.971 542.286 523.505 507.366
Retained Earnings (Accumulated Deficit) -682.315 -595.407 -504.542 -453.527 -292.173
Other Equity, Total -0.897 -0.224 -0.09445 -0.06642 -0.069
Total Liabilities & Shareholders’ Equity 254.596 251.211 70.784 98.297 275.566
Total Common Shares Outstanding 66.6887 61.2285 45.1093 41.4856 41.2107
Total Receivables, Net 0.484 0.623 0.772 0.704 0.563
Accounts Receivable - Trade, Net 0.484 0.623 0.772 0.704 0.563
Goodwill, Net 0 18.504
Intangibles, Net 6.973 7.048 7.123 7.199 7.273
Current Port. of LT Debt/Capital Leases 0 0.111 0.142
Deferred Income Tax 0.367 0.367 0.367 0.549 0.549
Total Inventory 0 0
Other Current Assets, Total 4.966 6.162
Long Term Debt 0 10.653 0 29.914
Capital Lease Obligations 0 0.021
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Total Current Assets 184.361 231.55 256.573 259.354 190.881
Cash and Short Term Investments 170.803 217.571 248.062 248.603 179.622
Cash & Equivalents 44.722 45.277 61.653 68.264 36.342
Short Term Investments 126.081 172.294 186.409 180.339 143.28
Total Receivables, Net 0.686 0.484 0.597 0.637 0.633
Accounts Receivable - Trade, Net 0.686 0.484 0.597 0.637 0.633
Prepaid Expenses 12.872 13.495 7.914 10.114 10.626
Total Assets 229.705 254.596 267.632 277.976 226.527
Property/Plant/Equipment, Total - Net 4.546 3.779 4.021 4.343 4.531
Property/Plant/Equipment, Total - Gross 11.528 10.374 10.25 10.217 10.056
Accumulated Depreciation, Total -6.982 -6.595 -6.229 -5.874 -5.525
Intangibles, Net 6.954 6.973 6.992 7.011 7.03
Long Term Investments 33.602 12.242 0 7.221 23.955
Other Long Term Assets, Total 0.242 0.052 0.046 0.047 0.13
Total Current Liabilities 18.258 21.938 19.789 16.217 16.726
Accounts Payable 8.19 10.351 7.667 5.703 8.121
Accrued Expenses 3.237 5.979 4.596 3.626 2.9
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 6.831 5.608 7.526 6.888 5.705
Total Liabilities 52.895 56.975 47.794 42.224 46.328
Total Long Term Debt 0 0 0 0 0
Long Term Debt 0
Deferred Income Tax 0.367 0.367 0.367 0.367 0.367
Other Liabilities, Total 34.27 34.67 27.638 25.64 29.235
Total Equity 176.81 197.621 219.838 235.752 180.199
Redeemable Preferred Stock 0 0 0 0 0
Common Stock 0.001 0.001 0.001 0.001 0.001
Additional Paid-In Capital 887.638 880.832 875.982 871.805 795.366
Retained Earnings (Accumulated Deficit) -710.475 -682.315 -654.68 -634.728 -614.196
Other Equity, Total -0.354 -0.897 -1.465 -1.326 -0.972
Total Liabilities & Shareholders’ Equity 229.705 254.596 267.632 277.976 226.527
Total Common Shares Outstanding 67.206 66.6887 66.6796 66.6676 61.7375
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -86.908 -90.865 -51.015 -161.354 -132.738
Cash From Operating Activities -67.567 -52.134 -38.633 -96.445 -100.811
Cash From Operating Activities 0.797 0.923 1.324 6.409 1.879
Non-Cash Items 19.739 39.151 13.6 61.203 20.61
Changes in Working Capital -1.195 -1.343 -2.36 -2.703 9.438
Cash From Investing Activities 12.628 -167.632 6.387 105.679 9.367
Capital Expenditures -0.605 -0.308 -0.453 -1.613 -1.356
Other Investing Cash Flow Items, Total 13.233 -167.324 6.84 107.292 10.723
Cash From Financing Activities 72.867 225.052 18.372 -30.316 128.261
Issuance (Retirement) of Stock, Net 72.901 239.659 7.807 0.207 100.782
Net Change in Cash 17.928 5.286 -13.874 -21.082 36.817
Deferred Taxes 0 -0.182 0 0
Financing Cash Flow Items -0.034 -3.124 -0.211 28.127
Issuance (Retirement) of Debt, Net -11.483 10.776 -30.523 -0.648
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -28.16 -86.908 -59.273 -39.321 -18.789
Cash From Operating Activities -26.353 -67.567 -48.452 -40.635 -20.969
Cash From Operating Activities 0.198 0.797 0.607 0.414 0.208
Non-Cash Items 6.006 19.739 7.826 1.438 1.146
Changes in Working Capital -4.397 -1.195 2.388 -3.166 -3.534
Cash From Investing Activities 25.798 12.628 9.926 8.709 29.932
Capital Expenditures -0.553 -0.605 -0.5 -0.35 -0.164
Other Investing Cash Flow Items, Total 26.351 13.233 10.426 9.059 30.096
Cash From Financing Activities 0 72.867 72.83 72.841 0.03
Financing Cash Flow Items 0 -0.034 -0.034 -0.023 -0.007
Issuance (Retirement) of Stock, Net 0 72.901 72.864 72.864 0.037
Issuance (Retirement) of Debt, Net 0
Net Change in Cash -0.555 17.928 34.304 40.915 8.993
Deferred Taxes

Aclaris Therapeutics Inc Company profile

About Aclaris Therapeutics Inc

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on developing drug candidates for immuno-inflammatory diseases. The Company is focused on leveraging its experience in drug discovery and development and kinase inhibition to develop small molecule therapies to help people impacted immuno-inflammatory conditions. The Company’s drug candidates are Zunsemetinib (ATI-450), ATI-1777 and ATI-2138. The Company’s ATI-450, an investigational oral, small molecule selective MK2 inhibitor compound, for the treatment of rheumatoid arthritis. Its ATI-1777, an investigational topical soft-JAK 1/3 inhibitor compound, for the treatment of atopic dermatitis. The Company is engaged in developing ATI-2138, its investigational oral inhibitor compound, as a potential treatment for T-cell mediated autoimmune diseases. It is also developing oral gut biased JAK inhibitors, as a potential treatment for inflammatory bowel disease.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Aclaris Therapeutics Inc revenues increased 4% to $6.8M. Net loss before extraordinary items increased 78% to $90.9M. Revenues reflect Therapeutics segment increase of 34% to $932K, Contract Research segment increase of 1% to $13.4M. Higher net loss reflects Therapeutics segment loss increase from $31.5M to $67.7M, Corporate segment loss increase of 16% to $20.6M.

Industry: Biotechnology & Medical Research (NEC)

640 Lee Rd Ste 200
WAYNE
PENNSYLVANIA 19087-5636
US

News

EUR/USD tests key support

EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

14:32, 21 September 2023
Bank of England building

BoE leaves rates unchanged, GBP drops further as investors look for more clarity

The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

11:45, 21 September 2023
British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

GBP softer after CPI surprise, JPY focused on any further hints from Ueda

GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

12:42, 20 September 2023

How to Trade The Break & Retest

In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

11:59, 20 September 2023

Cable coils near lows ahead of Fed and BoE rate decisions

It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.

14:16, 19 September 2023

FTSE 100 Technical Outlook - 18 September 2023

In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.

06:55, 19 September 2023
View of the City of London’s illuminated financial district skyline at dusk

Market Analysis: FTSE 100 boosted by ECB rate hike end and iron ore rally

The FTSE 100 rose over 2% on Thursday as the ECB announced no more rate hikes for now.

13:46, 15 September 2023

People also watch

BTC/USD

26,680.30 Price
+0.190% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 85.00

Oil - Crude

89.95 Price
+0.690% 1D Chg, %
Long position overnight fee 0.0349%
Short position overnight fee -0.0568%
Overnight fee time 21:00 (UTC)
Spread 0.030

ETH/USD

1,596.06 Price
+0.400% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 5.40

XRP/USD

0.52 Price
+0.670% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01192

Still looking for a broker you can trust?

Join the 555.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading